TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Reports Private Market Data & Analytics Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Reports
Private Market Data & Analytics
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Companies / Passage Bio Stock

Passage Bio Stock

passagebio.comHealthcareFounded: 2018Funding to Date: $225.5MM

Passage Bio is a genetic medicines company focused on developing a deep pipeline of adeno-associated virus (AAV) delivered therapeutics for the treatment of rare monogenic central nervous system disorders (CNS).

Learn more about Passage Bio IPO
Register for Details

For more details on financing and valuation for Passage Bio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Passage Bio.

Register Today

Team

Management Team

Jill Quigley JD
Chief Operating Officer, Operations
Gary Romano Ph.D
Chief Medical Officer
Tadataka Yamada MD
Co-Founder & Chairman
Richard Morris
Chief Financial Officer, Finance
James Wilson Ph.D
Co-Founder & Chief Scientific Advisor
Bruce Goldsmith Ph.D
Chief Executive Officer & Board Member
Alex Fotopoulos
Chief Technology Officer, Technology
Stephen Squinto Ph.D
Co-Founder, Board Member & Acting Head of R&D

Board Members

Bruce Goldsmith Ph.D
Sandip Kapadia
Thomas Woiwode Ph.D
Versant Venture Management
Liam Ratcliffe Ph.D
Stephen Squinto Ph.D
Patrick Heron
Frazier Healthcare Partners
Saqib Islam JD
Tadataka Yamada MD

Other companies like Passage Bio in the Healthcare sector

Neuralink
Sector
Healthcare
Last Round Est. Valuation
$2.15B
Colossal Biosciences
Sector
Healthcare
 
 
Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.67B
Synchron
Sector
Healthcare
Last Round Est. Valuation
$400.53MM
Grail
Sector
Healthcare
Last Round Est. Valuation
$4.26B
OURA
Sector
Healthcare
 
 
Mammoth Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.08B
Cytonics
Sector
Healthcare
 
 
Precision Neuroscience
Sector
Healthcare
 
 

News

Genomeweb 05/03/2021
InformedDNA Partners With Gene Therapy Firm Passage Bio on Dementia Genetic Testing
Xconomy 02/28/2020
Xconomy: Passage Bio's IPO Raises $216M to Fund Gene Therapy Studies
Gene therapy developer Passage Bio priced its initial public offering at $18 per share, raising $216 million---72 percent more than it originally planned
Xconomy 02/14/2019
Xconomy: Passage Bio Gets $116M As Wilson, Yamada Team Up On Gene Therapy Again
Longtime biopharmaceutical executive Tachi Yamada helped keep the work of gene therapy pioneer James Wilson alive 20 years ago when Wilson was mired in

Trending Companies

Frequently Asked Questions